Haig Aghajanian/LinkedIn
Jul 1, 2025, 07:18
Haig Aghajanian: AbbVie will Acquire Capstan Therapeutics
AbbVie announced it will acquire Capstan Therapeutics in a deal valued at up to $2.1 billion, marking a major step forward in its efforts to reshape immunology care through cutting-edge therapies. The acquisition includes Capstan’s novel in vivo CAR-T platform and its lead asset CPTX2309.
Haig Aghajanian, Co-Founder and Head of Research at Capstan Therapeutics, commented on the announcement on LinkedIn:
“Happy to share this news. Great for patients!”
The deal underscores AbbVie’s growing investment in next-generation treatments and highlights Capstan’s rapid rise as a key innovator in the field.
More posts featuring AbbVie.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2025, 15:24
Sep 7, 2025, 14:57
Sep 7, 2025, 14:41
Sep 7, 2025, 14:23
Sep 7, 2025, 14:05